Beijing launched Chinese patent medicine band volume purchased 19 exclusive varieties selected

Beijing will carry out the procurement of Chinese patent medicine band. On July 29, the Beijing Municipal Medical Security Bureau issued the "Notice on the Procurement of Beijing Municipal Medicine Bring Procurement in 2022", which aims to implement the normally institutionalized and institutionalized development of drugs Behavior, reduce the price of drug deficiency.

According to the above notice, the procurement of Beijing with this volume, in accordance with the principles of classification and policies, incorporates 64 drugs with sufficient market competition into the scope of band -linked drugs, and 20 drugs with relatively insufficient market competition are included in the scope of band negotiated drugs. Carry out the procurement of this Chinese patent medicine. According to reporters, the collection of Chinese patent medicines involving multiple sales of hundreds of millions of yuan, in addition, including exclusive varieties such as Lianhua Qing Plague capsule entered the collection list.

It is worth mentioning that following the purchase of the centralized band in Hubei Medicine Alliance, after the Six Provincial Medicine Collection Alliances, including Shandong, Anhui and other places, China also launched the procurement of Chinese patent band. "At present, the procurement of Chinese patent medicines is mostly carried out in the local area. At the national level, Sino -patent medicine collection is not launched. At present, it is difficult to uniform standards for the collection of Chinese medicines. Daily reporter said.

The purchase of Chinese patent band volume is the next city

Exclusive variety price changes attract attention

According to the above notice, Beijing's concentrated procurement of Chinese patent medicines mainly includes two types of band linkage and volume negotiations.

Among them, the volume of the provincial or provincial alliances of the provincial level or provincial alliances of the band volume is based on the level of purchase price of inter -provincial alliance. Provincial or inter -provincial alliances are based on the price level, formulate reference prices of drug transactions, and conduct quantity negotiations by inviting bargaining and linked prices.

In the quotation session, the above notice pointed out that according to the selected price (including the proposed middle -elected price of the bid for publication) and the current prices of the provinces of the country according to the same drug in various provinces or provincial alliances, the upper limit of the applied drug quotation (transaction transactions (transactions Reference Price). Among them, the quantity linkage drugs formulate the upper limit of quotation, that is, there are products with the prices of provincial or inter -provincial alliances to procurely procurement. Enterprise quotes must not be higher than the lowest prices of the product band purchase price and the current lowest price of the provinces. The products that are selected in the selected price in the league are not higher than the average level of the selected price in the same group of products and the current lowest price in each province.

In response to the drug negotiating drugs, the Beijing Medical Security Bureau will formulate a trading reference price. The reference price of the transaction shall not be higher than the price of the provincial or inter -provincial alliance in the provincial company and the current lowest price of the provincial provincial league.

It is worth mentioning that the exclusive variety of negotiations have become the focus of this collection. According to the information screening of the State Drug Administration's official website, the reporter of "Securities Daily" showed that in the procurement of Chinese patent bands in Beijing, compound Danshen Di Pills, Xiyan Ping injection, Suhuang relieving capsules, Lianhua Qingjuan granules/ 19 varieties such as capsules are exclusive to the enterprise.

"The collection of the exclusive varieties of Chinese medicines is mainly from the perspective of alternativeness. If the alternativeness of Chinese medicine is strong, the price is expected to fall at the negotiation."

Some analysts believe that the price reduction of exclusive varieties may be relatively mild. Prior to this, on April 8, 2022, the results of the Sino -Yaest P newral medicine collection of the six provinces of Guangdong announced the results. According to the research report issued by CITIC Securities, the average price decline of the bidded varieties in the collection of integrated bidders meets the expectations, and the exclusive variety has a lower decrease. From the perspective of the average decline in the price of the bidding varieties, the average decrease of the unique product to win the bid was 67.8%, and the average decrease of the exclusive product to win the bid was 21.8%.

There is also pressure to choose medicines without choosing medicines

Forcing companies to continue to innovate

The selected medicines are facing pressure to reduce prices with quantities, while unbelized medicines are facing pressure on the network and suspending transactions.

On July 25, Gansu Province issued the "Notice on Publicizing the Report results of the Reported Pharmaceutical Hanging Network of Hubei Medicine Alliance for Publication of Hubei Medicine Alliance", showing that a total of 123 non -selected drugs were applied for the purchase of unauthorized procurement of the Hubei Medicine Alliance, which was intended to be included in monitoring 10 of the settlement system transactions are intended to be included in 9 collecting platform transactions, 12 to the network, and 7 original platform transactions are retained, and 85 transactions are planned to suspend transactions.

On June 15th, the "Notice on the Propaganda of the first batch of inter -Provincial Association of Pharmaceuticals Provincial Pharmaceutical Association Bringing Various Various Various Various Various Various Various Various Various Various Various Capital Version and Medical Insurance Payment Standards" issued by Hubei Provincial Pharmaceutical Price and Bidding Procurement Management Service Network was notified. " Among the first batch of provincial -level alliances of Sinop Administrative Medicine, a total of 227 drugs will be suspended in the net in the non -secondary variety under the name of the same medicine.

"Judging from the progress of the procurement of Chinese medicine band volume, Sino -Pharmaceutical Companies must innovate to promote development. The days when they eat old -fashioned survival are over." Shi Lichen introduced to reporters that the enthusiasm of China Pharmaceutical Enterprise has low enthusiasm for research and development. In the future The development model must be changed.

From the perspective of specific enterprise R & D investment, only a few enterprises have made large -scale research and development investment.Data show that in 2021, 28 Chinese medicine enterprises have invested more than 100 million yuan in R & D, of which Baiyunshan, Yiling Pharmaceutical, Tasses, Buchang Pharmaceuticals, China Resources Pharmaceuticals, Jichuan Pharmaceuticals, Kangyuan Pharmaceutical R & D investment exceeds the total amount of R & D investment exceeding the total amount of research and development in excess500 million yuan.In contrast, there are also less than 50 million yuan in R & D investment in Chinese medicine companies, of which 8 Chinese medicine companies have invested less than 10 million yuan.Judging from the proportion of research and development investment in operating income, the value of 44 Chinese medicine listed companies is less than 4%.The total R & D investment of six pharmaceutical companies accounts for less than 1%of operating income."In the future, traditional Chinese medicine companies must also refer to pharmaceutical companies to force traditional Chinese medicine companies to conduct research and development and innovation investment in the model of procurement." Shi Lichen believes.

- END -